- Oral presentation
- Open Access
Lack of recall response to Tax in ATL and HAM/TSP patients but not in asymptomatic carriers of human T-cell leukemia virus type 1
© Manuel et al; licensee BioMed Central Ltd. 2014
- Published: 7 January 2014
- Asymptomatic Carrier
- Proviral Load
- Spastic Paraparesis
- Therapeutic Vaccine
- Chronic Viral Infection
The immunopathogenic mechanisms responsible for debilitating neurodegenerative and oncologic diseases associated with human T-cell leukemia virus type 1 (HTLV-1) are not fully understood. In this respect, a patient cohort from HTLV-1 endemic region that included seronegative controls (controls), asymptomatic carriers (ACs), and patients with adult T-cell leukemia (ATL) or HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) was analyzed for CD8+ T cells functionality in response to the viral antigen Tax and a superantigen SEB. Overall, there was a poor recall response to Tax and less polyfunctionality in cells from ATL and HAM/TSP patients but not in ACs explaining why these cells remain ineffective in limiting viral burden and controlling disease progression. On the other hand, response to superantigen SEB was similar in all the groups, suggesting that the observed defects in CD8+ T cells are not generalized but rather HTLV-specific. As an underlying mechanism, programmed death-1 (PD-1) receptor was found to be highly unregulated in Tax-responsive cells from ATL and HAM/TSP but not from ACs and directly correlated with the lack of polyfunctionality in these individuals. Further, an opposite dynamic was observed between PD-1 and MIP-1α with proviral loads revealing new avenues of understanding the immunopathogenesis of human chronic viral infections. Additionally, we identified key cytokine signatures defining the immune activation status of clinical samples by the luminex analyses. Collectively, our findings suggest that reconstitution of fully functional CTLs, stimulation of MIP-1α expression, and/or blockade of the PD-1 pathway as potential approaches for immunotherapy and therapeutic vaccine against HTLV-mediated diseases.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.